

USSN 10/731,854

CT-2709 NP

The applicants have addressed all 112 issues and note that no prior art has been cited against the subgenus. They therefore respectfully request the examiner to examine claim 1 on the merits.

Finally, The applicants intend to rejoin method of use claims 12-17 for allowed compound claims under MPEP 821.04.

Rejection under 35 USC 112. The examiner rejected claim 1 for not being enabled with respect to the term "solvate." The applicants deleted the term solvate in claim 1. The applicants found no other occurrences of this term in other claims.

The applicants believe the application is now allowable and respectfully request favorable reconsideration. If any issues remain regarding the allowance of this application, the examiner is respectfully invited to contact the applicants' agent, James Epperson, by phone (203-677-6974), fax (203-677-6900), or e-mail (james.epperson@bms.com).

Respectfully submitted,

Date: 1/5/2005
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

James Epperson
James Epperson
Agent for Applicants
Reg. No. 52,867
Phone: (203) 677-6974